COAST: Comparison of Baseline Characteristics and Ixekizumab Response Through Week 52 by Sex Among Patients With Axial Spondyloarthritis

June 2-5, 2021; Virtual
Although disease activity improved with ixekizumab treatment regardless of sex, time to improvement and peak response was longer for females vs males.
Format: Microsoft PowerPoint (.ppt)
File Size: 358 KB
Released: July 26, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

Slides featuring expert discussion of managing the physical and emotional elements of pediatric psoriasis

Victoria Garcia-Albea, NP, DCNP Robert Sidbury, MD, MPH Released: February 8, 2022

Interactive video roundtable featuring expert discussion of managing the physical and emotional elements of pediatric psoriasis.

Victoria Garcia-Albea, NP, DCNP Robert Sidbury, MD, MPH Physicians: maximum of 0.75 AMA PRA Category 1 Credits Nurse Practitioners: 0.75 NAPNAP CE contact hour, 0.25 pharmacology content Released: February 7, 2022 Expired: February 6, 2023

Expert insights from ACR 2021, including the most important data to clinical practice on the management of axPsA and axSpA, from Clinical Care Options (CCO)

Philip Mease, MD, MACR Released: December 23, 2021

Expert insights from ACR 2021, including the most important data for clinical practice on the management of axSpA and axPsA, from Clinical Care Options (CCO)

Atul Deodhar, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 22, 2021 Expired: December 21, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings